Literature DB >> 8696732

Resection of hepatocellular carcinoma in patients with cirrhosis.

J Balsells1, R Charco, J L Lazaro, E Murio, V Vargas, E Allende, C Margarit.   

Abstract

Between 1987 and 1993, 53 hepatic resections for hepatocellular carcinoma (HCC) were performed in 51 patients with cirrhosis. Limited hepatic resection was performed in 66 per cent of patients. The postoperative mortality rate was 13 per cent. The tumours recurred in 27 patients (53 per cent), and the cumulative recurrence rate at 1 and 4 years was 41 and 89 per cent, respectively. Mean time to recurrence was 11.7 months and the most frequent site was the liver (21 patients). The only significant risk factor for recurrence was symptomatic tumours. The recurrence rate of HCC in patients with cirrhosis with surgical resection alone is high and actuarial survival at 4 years is very low. Other approaches to the treatment of HCC in patients with cirrhosis require consideration.

Entities:  

Mesh:

Year:  1996        PMID: 8696732     DOI: 10.1002/bjs.1800830610

Source DB:  PubMed          Journal:  Br J Surg        ISSN: 0007-1323            Impact factor:   6.939


  22 in total

1.  Extended hepatic resection for hepatocellular carcinoma in patients with cirrhosis: is it justified?

Authors:  Ronnie Tung Ping Poon; Sheung Tat Fan; Chung Mau Lo; Chi Leung Liu; Chi Ming Lam; Wai Kei Yuen; Chun Yeung; John Wong
Journal:  Ann Surg       Date:  2002-11       Impact factor: 12.969

2.  Factors associated with disease survival after surgical resection in Chinese patients with hepatocellular carcinoma.

Authors:  Li Qiang; Li Huikai; Kelly Butt; P Peter Wang; Xishan Hao
Journal:  World J Surg       Date:  2006-03       Impact factor: 3.352

Review 3.  Image-guided percutaneous ablation therapies for hepatocellular carcinoma.

Authors:  Shuichiro Shiina
Journal:  J Gastroenterol       Date:  2009-01-16       Impact factor: 7.527

4.  High expression of Snail mRNA in blood from hepatocellular carcinoma patients with extra-hepatic metastasis.

Authors:  Ae Lyoung Min; Jong Young Choi; Hyun Young Woo; Jin Dong Kim; Jung Hyun Kwon; Si Hyun Bae; Seung Kew Yoon; Seung Hun Shin; Yeun Jun Chung; Chan Kwon Jung
Journal:  Clin Exp Metastasis       Date:  2009-06-16       Impact factor: 5.150

5.  Clinicopathologic features and risk factors for extrahepatic recurrences of hepatocellular carcinoma after curative resection.

Authors:  Toshiya Ochiai; Hisashi Ikoma; Kazuma Okamoto; Yukihito Kokuba; Teruhisa Sonoyama; Eigo Otsuji
Journal:  World J Surg       Date:  2012-01       Impact factor: 3.352

6.  Indication of hepatectomy for cirrhotic patients with hepatocellular carcinoma classified as Child-Pugh class B.

Authors:  Hideki Nakahara; Toshiyuki Itamoto; Koji Katayama; Hideki Ohdan; Hiroshi Hino; Makoto Ochi; Hirotaka Tashiro; Toshimasa Asahara
Journal:  World J Surg       Date:  2005-06       Impact factor: 3.352

7.  Concurrent and subsequent radiofrequency ablation combined with hepatectomy for hepatocellular carcinomas.

Authors:  Dongil Choi; Hyo K Lim; Hyunchul Rhim
Journal:  World J Gastrointest Surg       Date:  2010-04-27

8.  Preventive effect of regional radiotherapy with phosphorus-32 glass microspheres in hepatocellular carcinoma recurrence after hepatectomy.

Authors:  Xiao-Ming Wang; Zhen-Yu Yin; Ren-Xiang Yu; You-Yuan Peng; Ping-Guo Liu; Guo-Yang Wu
Journal:  World J Gastroenterol       Date:  2008-01-28       Impact factor: 5.742

9.  Primary liver resection for patients with cirrhosis and hepatocellular carcinoma: the role of surgery in BCLC early (A) and intermediate stages (B).

Authors:  Richard Bell; Sanjay Pandanaboyana; J Peter A Lodge; K Raj Prasad; Rebecca Jones; Ernest Hidalgo
Journal:  Langenbecks Arch Surg       Date:  2016-07-25       Impact factor: 3.445

10.  Surgical treatment of extrahepatic recurrence of hepatocellular carcinoma.

Authors:  Fumitoshi Hirokawa; Michihiro Hayashi; Yoshiharu Miyamoto; Mitsuhiro Asakuma; Tetsunosuke Shimizu; Koji Komeda; Yoshihiro Inoue; Kazuhisa Uchiyama
Journal:  Langenbecks Arch Surg       Date:  2014-07-17       Impact factor: 3.445

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.